Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

BioNTech Acquires Biotheus, Gains Control of Investigational Bispecific Antibody

Nov 13, 2024•over 1 year ago

Contract Type

partnership

MainzBiotechnologyHealth CareTherapeuticsBiopharma

Description

BioNTech has announced the acquisition of development partner Biotheus, which includes gaining full control of an investigational bispecific antibody aimed at dethroning checkpoint inhibitors as the standard treatment for solid tumors. The agreement involves an $800 million upfront payment, along with the promise of up to $150 million in certain milestones.

Company Information

Company

BioNTech

Location

Mainz, Rhineland-Palatinate, Germany

About

BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for BioNTech's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.